<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04090463</url>
  </required_header>
  <id_info>
    <org_study_id>PancFORT</org_study_id>
    <nct_id>NCT04090463</nct_id>
  </id_info>
  <brief_title>IORT on Borderline Resectable Pancreatic Cancer</brief_title>
  <acronym>PancFORT</acronym>
  <official_title>A Phase II Study of Primary Chemotherapy, Stereotactic Body Radiation Therapy, and Intraoperative Radiation Therapy in Borderline Resectable Pancreatic Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universita di Verona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universita di Verona</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II study investigates the efficacy of IORT for patients with borderline resectable
      pancreatic cancer. The purpose of the study is to investigate whether the addition of IORT,
      after FOLOFIRINOX-base chemotherapy, and SBRT, increases the 3-year survival rate. A total of
      101 patients will be enrolled, and these patients will receive IORT of 10 to 20 Gy, according
      to the resection status (to the tumor bed after resection, or to the tumor in situ in case of
      non-resection).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Treatment outcomes of borderline resectable pancreatic cancer are still poor even after
      completion of FOLFIRINOX-based chemotherapy and radical resection. A growing body of
      literature is demonstrating that Stereotactic body radiation therapy (SBRT) and
      Intraoperative radiotherapy (IORT), within a multimodal approach, allow to obtain better
      oncological outcome, at the price of low to negligible rates of morbidity and mortality. The
      investigators hypothesize that a &quot;total neoadjuvant&quot; scenario, with the best current therapy,
      based on up to 6 months of FOLFIRINOX (minimum 4), SBRT and IORT (in situ or after surgery)
      would increase the disease-specific survival of borderline resectable pancreatic cancer
      patients. An historical cohort will be used as a comparison group.

      Considering the intention-to-treat design and the institutional rates of chemotherapy
      completion and exploration/resection of borderline resection pancreatic cancer patients, a
      total of 100 patients will be enrolled in this phase II trial. Patients submitted to IORT,
      will receive IORT of 10 to 20 Gy according to the resection status (to the tumor bed after
      resection, or to the tumor in situ in case of non-resection).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2019</start_date>
  <completion_date type="Anticipated">June 30, 2026</completion_date>
  <primary_completion_date type="Anticipated">October 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-specific survival</measure>
    <time_frame>36 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with treatment-related adverse events as assessed by CTCAE v4.0</measure>
    <time_frame>36 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of margin-free surgery</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of surgical complications</measure>
    <time_frame>Up to 90 days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Resection rate</measure>
    <time_frame>Intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Borderline Resectable Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>IORT group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intraoperative administration of 10 to 20 Gy after surgery or as an &quot;in situ&quot; treatment in case resection will not be performed</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Intraoperative radiotherapy</intervention_name>
    <description>IORT will be delivered as follows:
Radical resection --&gt; delivery of 10-15 Gy to the tumor bed
Non radical resection --&gt; delivery of 15-20 Gy to the tumor &quot;in situ&quot;</description>
    <arm_group_label>IORT group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  • Biopsy-proven, previously untreated borderline resectable PC, defined according to
             the NCCN guidelines v1.2019;

               -  Age 18-80 years;

               -  Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1;

               -  Adequate bone marrow function (absolute neutrophil count ≥1500 per cubic
                  millimeter; platelet count ≥100.000 per cubic millimeter; hemoglobin level ≥10 g
                  per deciliter), liver function (serum total bilirubin level ≤1.5 times the upper
                  limit of the normal range), and renal function (creatinine clearance ≥50 ml per
                  minute);

               -  Ability to understand the characteristics of the clinical trial;

               -  Written informed consent.

        Exclusion Criteria:

          -  • Ampullary, biliary, or duodenal adenocarcinoma; pancreatic adenocarcinoma in the
             background of an intraductal papillary mucinous neoplasia (IPMN), other uncommon
             pancreatic adenocarcinomas (acinar-cell, squamous, giant-cell osteoclastic-like);

               -  Invasive cancer in the last 5 years requiring radiation therapy to the upper
                  abdomen or chemotherapy;

               -  Symptomatic heart failure or coronary artery disease;

               -  Pregnant or lactating women;

               -  Impaired mental state or language problems.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Giuseppe Malleo, MD, PhD</last_name>
    <phone>00458126516</phone>
    <email>giuseppe.malleo@univr.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Salvatore Paiella, MD, PhD</last_name>
    <phone>00390458126009</phone>
    <email>salvatore.paiella@univr.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>General and Pancreatic Surgery Unit, Pancreas Institute, University of Verona Hospital</name>
      <address>
        <city>Verona</city>
        <zip>37134</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erica Secchettin, PharmD</last_name>
      <phone>00390458126254</phone>
      <email>erica.secchettin@univr.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Palta M, Willett C, Czito B. The role of intraoperative radiation therapy in patients with pancreatic cancer. Semin Radiat Oncol. 2014 Apr;24(2):126-31. doi: 10.1016/j.semradonc.2013.11.004. Review.</citation>
    <PMID>24635869</PMID>
  </results_reference>
  <results_reference>
    <citation>Krempien R, Roeder F. Intraoperative radiation therapy (IORT) in pancreatic cancer. Radiat Oncol. 2017 Jan 10;12(1):8. doi: 10.1186/s13014-016-0753-0. Review.</citation>
    <PMID>28069018</PMID>
  </results_reference>
  <results_reference>
    <citation>Cai S, Hong TS, Goldberg SI, Fernandez-del Castillo C, Thayer SP, Ferrone CR, Ryan DP, Blaszkowsky LS, Kwak EL, Willett CG, Lillemoe KD, Warshaw AL, Wo JY. Updated long-term outcomes and prognostic factors for patients with unresectable locally advanced pancreatic cancer treated with intraoperative radiotherapy at the Massachusetts General Hospital, 1978 to 2010. Cancer. 2013 Dec 1;119(23):4196-204. doi: 10.1002/cncr.28329. Epub 2013 Sep 4.</citation>
    <PMID>24006012</PMID>
  </results_reference>
  <results_reference>
    <citation>Murphy JE, Wo JY, Ryan DP, Jiang W, Yeap BY, Drapek LC, Blaszkowsky LS, Kwak EL, Allen JN, Clark JW, Faris JE, Zhu AX, Goyal L, Lillemoe KD, DeLaney TF, Fernández-Del Castillo C, Ferrone CR, Hong TS. Total Neoadjuvant Therapy With FOLFIRINOX Followed by Individualized Chemoradiotherapy for Borderline Resectable Pancreatic Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Oncol. 2018 Jul 1;4(7):963-969. doi: 10.1001/jamaoncol.2018.0329. Erratum in: JAMA Oncol. 2018 Oct 1;4(10):1439.</citation>
    <PMID>29800971</PMID>
  </results_reference>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>September 10, 2019</study_first_submitted>
  <study_first_submitted_qc>September 12, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2019</study_first_posted>
  <last_update_submitted>April 8, 2020</last_update_submitted>
  <last_update_submitted_qc>April 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universita di Verona</investigator_affiliation>
    <investigator_full_name>Salvatore Paiella, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pancreatic cancer</keyword>
  <keyword>Borderline resectable pancreatic cancer</keyword>
  <keyword>Intraoperative radiotherapy (IORT)</keyword>
  <keyword>Total neoadjuvant therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

